Azienda Ospedaliera Ospedali Riuniti Marche Nord
- Address
- lock Available on a paid plan
Cardiovascular Diseases and Cardio-oncology
At Azienda Ospedaliera Ospedali Riuniti Marche Nord, research in cardiovascular diseases focuses on improving prevention and treatment strategies for patients with complex heart-related conditions, including those with atrial fibrillation after PCI and people at risk of chemotherapy-induced cardiotoxicity. These studies are designed to assess safer antithrombotic care and explore ways to protect the heart during cancer treatment.
- Atrial fibrillation after coronary stenting: evaluating safer long-term antithrombotic treatment approaches
- Chemotherapy-induced cardiotoxicity in breast cancer: testing heart-protective strategies during cancer care
- Cardio-oncology: examining methods to reduce treatment-related cardiac complications
This area combines cardiology and cancer care to support better cardiovascular safety and treatment effectiveness for patients facing overlapping heart and oncology risks.
Hemic and Lymphatic Diseases
Clinical research in hemic and lymphatic diseases at this hospital covers several blood cancers and myeloproliferative disorders, with a strong emphasis on finding more effective and better-tolerated treatments. The studies include efforts to improve disease control in acute leukemia, myelofibrosis, polycythemia vera, and Philadelphia chromosome-positive acute lymphoblastic leukemia.
- Acute myeloid leukemia: evaluating treatment responses through minimal residual disease reduction
- Ph+ acute lymphoblastic leukemia: testing new treatment combinations to improve remission and survival
- Polycythemia vera: assessing therapies aimed at maintaining hematocrit control
- Myelofibrosis: studying symptom relief and spleen size reduction
These trials reflect a broader effort in hematology to refine disease monitoring and expand options for patients with challenging blood-related malignancies.
Neoplasms
Oncology research at Azienda Ospedaliera Ospedali Riuniti Marche Nord includes studies in lung cancer, colorectal cancer, pleural mesothelioma, and other advanced solid tumors. The trials are mainly designed to compare treatment effectiveness, improve survival outcomes, and identify better therapeutic sequences for patients with difficult-to-treat cancers.
- Non-small cell lung cancer: testing new immunotherapy combinations for advanced disease
- Metastatic colorectal cancer: comparing treatment sequences after prior therapy benefit
- Pleural mesothelioma: evaluating a targeted immunotherapy-based approach for PD-L1-positive disease
- Minimal residual disease in acute myeloid leukemia: assessing the impact of adding a targeted agent to standard care
Overall, this cancer research portfolio is centered on testing new therapies and refining treatment strategies for patients with advanced or resistant disease.
Respiratory Tract Diseases
Research in respiratory tract diseases at this site is mainly focused on advanced non-small cell lung cancer and pleural mesothelioma. The studies aim to improve survival, strengthen treatment response, and explore whether new combinations of immunotherapy and chemotherapy can offer better outcomes for people with aggressive thoracic cancers.
- Non-small cell lung cancer: comparing immunotherapy-based treatment combinations for newly diagnosed advanced disease
- Pleural mesothelioma: studying a new therapeutic option for patients with PD-L1-positive tumors
- Lung cancer: evaluating approaches intended to improve disease control and overall survival
These trials highlight a strong interest in thoracic oncology, with a focus on testing new therapies for patients with serious respiratory cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 54 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 52 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera Ospedali Riuniti Marche Nord
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) | Oslo University Hospital HF | Phase II | Not Recruiting | Aug 2022 | Dec 2023 |
IMP list
lock Showing 1 of 54 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 3 | Unknown | 2020-09-24 | 2021-09-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.